Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer
Open Access
- 3 July 2015
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12 (4) , 5246-5254
Abstract
The present study aimed to investigate whether the mammalian target of rapamycin (mTOR) signaling pathway is activated in invasive breast cancer. The expression levels of phosphorylated (p)‑mTOR at ser2448 were detected, as well as the expression levels of its downstream signaling molecules: Eukaryotic translation initiation factor 4E‑binding protein 1 (4E‑BP1), and p70 ribosomal protein S6 kinase 1 (S6K1). The correlation between p‑mTOR, p‑4E‑BP1, p‑S6K1, and the clinicopathological parameters of breast cancer were also determined. p‑mTOR, p‑4E‑BP1 and p‑S6K1 expression was detected in 285 breast cancer tumor samples and adjacent normal tissue samples using immunohistochemistry. The expression levels and the location of the proteins were analyzed and compared in the various tissue samples. Multivariate Cox regression was used to analyze the clinicopathological factors and prognosis associated with the tissue samples. The disease‑free survival rate was examined using survival analyses and Log‑rank tests. The results of the present study indicated that the expression levels of p‑mTOR, p‑4E‑BP1, and p‑S6K1 were significantly higher in breast cancer tissue, as compared with normal tissue (P0.05). In conclusion, the results of the present study suggested that p‑mTOR, p‑4E‑BP1, and p‑S6K1 are activated in invasive breast cancer. In addition, the exclusive expression of p‑4E‑BP1 and p‑S6K1 in the cytoplasm may be characteristic of progressive breast cancer. However, p‑mTOR, p‑4E‑BP1, and p‑S6K1 are not prognostic factors for breast cancer.Keywords
This publication has 52 references indexed in Scilit:
- Targeted Therapy for Breast Cancer PreventionFrontiers in Oncology, 2013
- Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populationsAnnals of Oncology, 2008
- Defining the Role of mTOR in CancerCancer Cell, 2007
- Ras, PI(3)K and mTOR signalling controls tumour cell growthNature, 2006
- Monitoring the decrease in breast cancer mortality in EuropeEuropean Journal Of Cancer Prevention, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 CasesJournal of Clinical Oncology, 2005
- Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinomaCancer, 2005
- Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate CancerCancer Research, 2004
- TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammalsMolecular and Cellular Endocrinology, 1999